What it's for (Indications)
- Favipiravir is an antiviral agent primarily indicated for the treatment of novel or re-emerging influenza virus infections in situations where other antiviral agents are either ineffective or contraindicated.
- Its use is generally reserved for public health emergencies or specific clinical circumstances where the benefit-risk profile is carefully considered.
- It has demonstrated activity against various RNA viruses in vitro, including influenza viruses, norovirus, and certain arboviruses.
- Clinical efficacy against influenza has been established in regions where it is approved, particularly for strains resistant to neuraminidase inhibitors or when conventional treatments are deemed insufficient.
- It should only be used when recommended by public health authorities or specialists.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for adults typically involves a loading dose of 1600 mg administered orally twice daily on day 1, followed by a maintenance dose of 600 mg orally twice daily for days 2 through 5. The total treatment duration is generally 5 days. For pediatric patients, dosage regimens are weight-based and should strictly follow specific guidelines from approved product labeling or clinical protocols. Dosage adjustments may be necessary in patients with renal or hepatic impairment, though specific guidelines can vary by region and product labeling; caution is advised in these populations. It is crucial to administer favipiravir as early as possible after symptom onset to maximize therapeutic benefit and achieve optimal clinical outcomes. Adherence to the prescribed regimen is vital for optimal antiviral efficacy and to minimize the risk of viral resistance development. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects of favipiravir include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain.
- Patients may also experience transient elevations in liver enzymes (ALT, AST), hyperuricemia (increased uric acid levels), and hematological abnormalities including neutropenia, leukopenia, and thrombocytopenia.
- Less frequently, but of clinical concern, are psychiatric symptoms such as abnormal behavior, hallucinations, and delirium, particularly noted in adolescent patients.
- Other reported adverse events can include rash, dizziness, headache, and allergic reactions.
- It is imperative that healthcare providers monitor patients for these potential adverse reactions throughout the treatment period, and patients should be advised to report any unusual or severe symptoms immediately.
Serious Warnings
- Black Box Warning: **SEVERE TERATOGENICITY AND EMBRYOTOXICITY; RISKS TO MALE REPRODUCTIVE HEALTH** Favipiravir is associated with a high risk of severe birth defects and embryonic lethality, as definitively demonstrated in multiple animal studies across different species. Therefore, favipiravir is absolutely contraindicated in pregnant women. Prior to initiating treatment, women of childbearing potential must undergo a reliable pregnancy test, such as a urine or serum test, to confirm non-pregnant status. These patients must use highly effective contraception continuously during treatment with favipiravir and for at least seven days after the last dose of favipiravir to prevent any potential fetal exposure. Healthcare providers must provide thorough counseling on the serious and irreversible risks of fetal exposure to favipiravir. For male patients, favipiravir is detected in human semen. Men whose partners are pregnant or of childbearing potential must use condoms consistently during sexual intercourse throughout treatment and for at least seven days after the last dose of favipiravir. Furthermore, male patients should refrain from donating sperm during treatment and for seven days following the cessation of favipiravir therapy. These stringent measures are critical to prevent unintended fetal exposure via seminal fluid and to mitigate the significant reproductive risks associated with favipiravir. The potential for irreversible harm to a developing fetus necessitates strict adherence to these precautions.
- Favipiravir carries several significant warnings that necessitate careful clinical consideration.
- It can cause a dose-dependent increase in serum uric acid levels, potentially leading to hyperuricemia and exacerbation of gout or new-onset gout attacks.
- Hepatic function should be monitored regularly through liver enzyme tests due to the risk of elevated transaminases, which may indicate liver injury.
- Caution is advised in patients with a history of psychiatric disorders, as favipiravir has been associated with neuropsychiatric events, including abnormal behavior.
- Drug interactions can occur with certain medications, including pyrazinamide (potentiating hyperuricemia) and repaglinide (increasing exposure), requiring careful assessment of concomitant therapy.
- Patients with severe renal or hepatic impairment may require dose adjustments or avoidance, as the pharmacokinetics in these populations are altered, potentially increasing drug exposure and the risk of adverse events.
- This medication is not recommended for routine use and should be reserved for specific indications as outlined by regulatory bodies.
How it Works (Mechanism of Action)
Favipiravir is an antiviral prodrug that undergoes intracellular phosphorylation by cellular enzymes, primarily hypoxanthine guanine phosphoribosyltransferase (HGPRT), to its active form, favipiravir-ribofuranosyl-5'-triphosphate (favipiravir-RTP). Favipiravir-RTP acts as a purine nucleoside analogue, which is then recognized as a substrate by the viral RNA-dependent RNA polymerase (RdRp). This incorporation into the nascent viral RNA chain leads to two primary inhibitory effects: it acts as a competitive inhibitor of nucleotide binding to the RdRp, and critically, it induces lethal mutagenesis (error catastrophe) in the viral genome. This accumulation of mutations prevents effective viral replication and transcription, thereby inhibiting the proliferation of various RNA viruses, including influenza viruses. This unique mechanism contributes to its broad-spectrum antiviral activity against numerous RNA viruses.